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Review the literature from 1990 to 2013 to determine known anatomic 
sites, risk factors, treatments, and outcomes of  head and neck squamous 
cell carcinoma (HNSCC) in sub-Saharan Africa.
Methods
Using a systematic search strategy, literature pertaining to HNSCC in 
sub-Saharan Africa was reviewed and patient demographics, anatomic 
sites, histology, stage, treatment, and outcomes were abstracted. The 
contributions of  human immunodeficiency virus (HIV), human 
papillomavirus (HPV) and behavioural risk factors to HNSCC in the 
region were assessed. 
Results
Of  the 342 papers identified, 46 were utilized for review, including 8611 
patients. In sub-Saharan Africa, the oropharyngeal/oral cavity was found 
to be the most common site, with 7750 cases (90% of  all cases). Few 
papers distinguished oropharyngeal from oral cavity, making identification 
of  possible HPV-associated oropharyngeal squamous cell carcinoma 
(SCC) difficult. SCC of  the nasopharynx, nasal cavity, or paranasal sinuses 
was identified in 410 patients (4.8% of  all cases). Laryngeal SCC was 
found in 385 patients (4.5% of  all cases), and only 66 patients (0.8% of  
all cases) with hypopharyngeal SCC were identified. In 862 patients with 
data available, 43% used tobacco and 42% used alcohol, and reported 
use varied widely and was more common in laryngeal SCC than that of  
the oropharyngeal/oral cavity. Toombak and kola nut use was reported to 
be higher in patients with HNSCC. Several papers reported HIV-positive 
patients with HNSCC, but it was not possible to determine HNSCC 
prevalence in HIV-positive compared to negative patients. Reports of  
treatment and outcomes were rare.
Conclusions
The oropharyngeal/oral cavity was by far the most commonly reported 
site of  HNSCC reported in sub-Saharan Africa. The roles of  risk factors 
in HNSCC incidence in sub-Saharan Africa were difficult to delineate 
from the available studies, but a majority of  patients did not use tobacco 
and alcohol.
Introduction
Sub-Saharan Africa is experiencing a rapidly increasing 
burden of  cancer-related morbidity and mortality. 
While annual deaths in the region resulting from human 
immunodeficiency virus (HIV),1 tuberculosis,2 and malaria3 
are steadily declining, cancer deaths are projected to increase 
by 85% between 2008 and 2030.3 Moreover, these projections 
assume static age-specific incidence rates and are based solely 
on projected population growth and aging. Population-based 
cancer registries, however, demonstrate increasing cancer 
incidence, likely resulting from HIV and westernization of  
lifestyles.5,6,7 This suggests future cancer burden in the region 
may be significantly underestimated.
Earlier cancer detection via screening, insights into tumour 
biology and pathogenesis, as well as improved treatments 
and supportive care, have contributed to increasing cancer 
survivorship in high-income countries. However, cancer 
patients in sub-Saharan Africa have largely not benefited 
from these advances and outcomes remain poor because 
of  severely limited resources for diagnosis and treatment, as 
well as possible differences in the aetiology and pathogenesis 
of  cancer in this region.8 
The sites of  lip, oral cavity, nasopharynx, other pharynx, 
and larynx, collectively, comprised the sixth most common 
cancer in sub-Saharan Africa, with 18,099 reported cases 
in 2008.9 Upper aerodigestive tract cancers are staged 
according to the American Joint Commission on Cancer 
(AJCC) staging manual, by site and sub-site, based on the 
complex anatomy and physiology of  the head and neck 
region. The aerodigestive anatomic sites delineated by 
AJCC are sinonasal, nasopharynx, oropharynx, oral cavity, 
hypopharynx, and larynx. Across all head and neck sites, the 
most common histology is squamous cell carcinoma (SCC).10 
Head and neck anatomy, as it pertains to staging cancers, 
requires specific training. There are only a limited number 
of  head and neck surgeons in sub-Saharan Africa, and this 
review highlights the need for better anatomic understanding 
and staging.
For head and neck squamous cell carcinoma (HNSCC) 
patients, tobacco and alcohol use have historically been 
the most common risk factors.11 Although tobacco use 
remains uncommon in most of  sub-Saharan Africa, tobacco 
companies are aggressively marketing cigarettes throughout 
the region, targeting youth in particular.12 Over the past 
several decades, tobacco use has increased by nearly 50% in 
low-and-middle-income countries (LMIC), generally, while 
simultaneously declining in high-income countries.13 
While tobacco use has decreased in high-income countries, 
HNSCC burden has not significantly declined, partly 
explained by the emergence of  human papillomavirus (HPV) 
as an aetiologic agent of  oropharynx (OP) squamous cell 
carcinoma.14 In sub-Saharan Africa, infectious agents play a 
directly causative role in one-third of  cancers,15 and HPV is 
the aetiologic agent of  cervical cancer, the most common 
cancer in the region.6 However, the contribution of  HPV 
to HNSCC in sub-Saharan Africa is not well described, 
particularly in settings where HIV is highly prevalent, 
and where HIV-infected individuals may have increased 
acquisition and persistence of  oncogenic HPV strains at 
multiple anatomic sites.16,17
This is a comprehensive review of  the literature pertaining 
to HNSCC in sub-Saharan Africa. We systematically 
reviewed the regional literature with respect to HNSCC, 
including summarizing all available data regarding patient 
demographics, behavioural risk factors, HIV, HPV, anatomic 
site, histology, stage, treatment, and outcomes. Limitations 




PubMed was searched for all English- or French-language 
papers identified using the MeSH terms “head and neck 
cancer”, “squamous cell carcinoma”, and “Africa”, and 
limiting results to studies of  human subjects. Additional 
papers were identified from a bibliographic search of  the 
studies identified. Since the HIV epidemic has had major 
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effects on the pattern of  malignancies in the region, 1990 
was chosen as the starting year for this review. Papers from 
North Africa were excluded, as were series reporting on 
fewer than five patients. For duplicative papers reporting 
on the same groups of  patients, we included the publication 
describing the largest series of  HNSCC patients specifically. 
Many studies reported on several pathologies of  oral, nasal, 
or laryngeal neoplasms, from which data regarding HNSCC 
were extracted. Given that sinonasal undifferentiated 
carcinoma (SNUC) and nasopharyngeal carcinoma (NPC) 
include SCC histologies, these subtypes were included. 
Data analysis
A standardized abstraction tool was developed to extract 
data from papers identified and to characterize studies 
based on inclusion and exclusion criteria. Data were 
abstracted from each paper with respect to primary tumour 
site or subsite, disease stage, patient sex, behavioural risk 
factors, patient HIV status, patient HPV status, treatment, 
complications, and outcomes. We described male-to-female 
ratios, substance use, HIV prevalence, HPV frequency, and 
tumour stage by summing the numbers of  patients across 
all studies, stratifying by anatomic site. Data were omitted if  
HNSCC patients could not be extrapolated from aggregate 
tumour data.
Anatomic classification
Anatomic sites were not uniformly reported or defined in 
the studies reviewed.  For our analysis, carcinomas were 
grouped as oral cavity (OC) and oropharynx (OP), nasal 
cavity (NC), nasopharynx (NP), paranasal sinuses, larynx, and 
hypopharynx (HP). The AJCC cancer staging manual was 
used to delineate these sites, as defined below.18 For papers 
including multiple anatomic sites, we analyzed carcinomas 
separately by anatomic site.
OC is defined as mucosal lip, buccal mucosa, alveolar ridge 
(gums or gingiva), retromolar trigone, hard palate, floor of  
mouth, and anterior two-thirds of  the tongue. OP includes 
the inferior surface of  the soft palate, tonsillar beds, tongue 
base, and lateral and posterior pharyngeal walls, from the level 
of  the soft palate to the tip of  the epiglottis. The dividing 
line between OC and OP is the junction of  the hard and soft 
palate and the lingual circumvallate papillae. It was frequently 
not possible to distinguish OC from OP based on available 
data, therefore these two anatomic sites were analyzed in 
aggregate. NC is anatomically defined as extending from 
the nares to the choanae, including the turbinates. NP was 
defined as extending posteriorly from the choanae, including 
the lateral and posterior pharyngeal walls, down to the 
free edge of  the soft palate. The paranasal sinuses include 
the maxillary, ethmoid, frontal, and sphenoid sinuses. The 
larynx subsites are the supraglottis, glottis, and subglottis. 
The supraglottis subsites are epiglottis, aryepiglottic folds, 
arytenoids and false vocal cords. The glottis includes the 
true vocal cords, and anterior and posterior commissures. A 
transglottic cancer extends through all three divisions of  the 
larynx. HP is defined as extending inferiorly from the level of  
the epiglottis to the oesophageal introitus and includes three 
subsites: the postcricoid region, the right and left pyriform 
sinuses, and the posterior pharyngeal wall.18  
Results
The initial PubMed search returned 330 papers, with an 
additional 12 papers identified using references of  papers 
from the initial search. Of  these 342 total papers, 60 
included HNSCC in Africa and were published after 1990. 
Fourteen articles were excluded, leaving 46 studies in this 
review. Two excluded studies described regions other than 
sub-Saharan Africa.19,20 Other excluded studies were a series 
of  patients with specifically late presentations of  benign 
and malignant orofacial tumours,21 virological studies 
of  pathology specimens without accompanying clinical 
data,22-24 and studies exclusively examining SCC metastases 
to salivary glands.25,26 We attempted to extrapolate HNSCC 
data from papers reporting SCC at multiple sites, but several 
papers were excluded because they only reported aggregate 
data, such that we could not distinguish HNSCC from the 
larger SCC group. Five papers that duplicated patients from 
other studies were excluded.27-31 Overall, 8611 patients were 
included in the review.
Demographics, anatomic sites, and histology
Twenty-nine papers were identified that included SCC of  
the OC/OP, with a total of  7750 patients (90% of  all cases 
identified, Table 1). The mean or median age of  patients 
ranged from 37 years in Kenya39 to 58 years in Ghana,47 
but there were insufficient patient-level data to report an 
aggregate mean or median age across all studies. The mean 
age of  37 was reported from a study of  exclusively HIV-
infected HNSCC patients in Kenya.39 The youngest mean 
age in a generalized OC/OP SCC population was 46 years 
from Congo.32 Male-to-female ratios ranged from 0.5:1 in 
Congo32 to 4:1 in South Africa.44 Overall, there were 2.3 
males per female with OC/OP SCC across all studies. The 
most common OC/OP subsites were the mandibular or 
maxillary alveolar ridge in 1007 cases (13%), followed by 
the tongue in 773 (10%). In 57% of  cases the site was not 
specified. OP sites were specified in only 171 cases (2%). 
The degree of  differentiation was described in 835 cases 
(11%). Well-differentiated, moderately differentiated, and 
poorly differentiated carcinomas comprised 42%, 37%, and 
25%, respectively. 
Ten studies, including 410 patients, reported data from 
patients with cancer of  the nasopharynx (NP), nasal cavity 
(NC), or paranasal sinuses (4.8% of  all cases, Table 2). Few 
of  these studies reported age and gender, but mean or 
median ages ranged from 4962 to 51 years,63 and male-to-
female ratios ranged from 1.7:163 to 2.3:1.61 Among SCCs 
of  the NC, NP, and paranasal sinuses, the maxillary sinus was 
the most common subsite, comprising 53% of  all tumours. 
Among NC, NP, and paranasal sinus SCCs, 71% were well-
differentiated. Of  the 73 NP carcinomas that were described 
with a WHO histologic classification, 26 (46%) were class I 
(keratinizing, differentiated SCC), while 47 (64%) were class 
II or III (undifferentiated carcinomas). 
Ten studies discussed laryngeal carcinoma, including 385 
patients (4.5% of  all cases, Table 3). Mean or median ages 
ranged from 49 years in Cameroon68 to 70 years in Nigeria.69 
Male-to-female ratios ranged from 6:1 in South Africa45 and 
Nigeria70 to 28:1 in Zimbabwe,67 and the average ratio was 
13:1. Lesion subsite was available for 240 patients and, of  
these, 62% were glottic. Two studies of  laryngeal SCC noted 
the degree of  histologic differentiation,  with the majority 
being well-differentiated tumours (63%).61,72 
Two studies from Senegal discussed HP SCC, including a 
study of  66 patients (0.8% of  all cases), aged 10 to 86 years, 
with a mean age of  33,74 and a study of  15 children, aged 10 
to 18 years, with a mean age of  15.75 The aggregate male-
to-female ratio was 0.9:1. Lesion subsite was recorded for 
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Table 1: Included studies of head and neck squamous cell carcinoma of the oral cavity and oropharynx in sub-Saharan Africa since 1990
LOCATION( YEAR AUTHOR N SITES        






Palate Tongue OP Not(
specified 
Central!            
DRC! 1999! Kayembe32!! 83! 14!(17%)! 11!(13%)! 7!(8%)! 6!(7%)! 17!(20%)! 20!(24%)! 7! 8!(10%)!
Sudan! 2010! Ibrahim33!! 192! 7! 7! 7! 7! 7! 7! 7! 192!(100%)!
Sudan! 1995! Idris34! 650! 7! 7! 7! 7! 7! 7! 7! 650!(100%)!
Sudan! 2010! Jalouli35! 217! 10!(5%)! 73!(34%)! 50!(23%)! 31!(14%)! 6!(3%)! 47!(22%)! 7! 7!
Sudan! 2012! Jalouli36! 20! 7! 7! 7! 7! 7! 7!(35%)! 7! 13!(65%)!
Eastern!            
Ethiopia! 1994! Neway37! 16! 7! 7! 7! 7! 7! 7! 7! 16!(100%)!
Kenya! 2008! Butt38! 9! 7! 7! 7!(78%)! 7! 2!(22%)! 7! 7! 7!
Kenya! 2012! Butt39! 16! 2!(13%)! 2!(13%)! 2!(13%)! 3!(19%)! 7! 5!(31%)! 2!(13%)! 7!
Kenya! 2007! Dimba40! 187! 10!(5%)! 32!(17%)! 31!(17%)! 32!(17%)! 25!(13%)! 35!(19%)! 1!(1%)! 21!(11%)!
Kenya! 1992! Maroo41! 17! 7! 7!(41%)! 3!(18%)! 4!(24%)! 2!(12%)! 1!(6%)! 7! 7!
Kenya! 1995! Onyango42! 580! 53!(9%)! 23!(4%)! 107!(18%)! 31!(5%)! 93!(16%)! 149!(26%)! 7! 124!(21%)!
Kenya! 2004! Onyango43! 821! 86!(10%)! 86!(10%)! 242!(29%)! 63!(8%)! 7! 220!(27%)! 124!(15%)! 7!
Southern!            
RSA! 1996! Hille44! 3070! 7! 7! 7! 7! 7! 7! 7! 3070!(100%)!
RSA! 2002! Pacella7
Norman45!
124! 7! 7! 7! 7! 7! 7! 7! 124!(100%)!
Zimbabwe! 2006! Chidzonga46! 313! 14!(4%)! 33!(11%)! 99!(32%)! 58!(19%)! 28!(9%)! 64!(20%)! 17!(5%)! 7!
Western!            
Ghana! 2009! Parkins47! 69! 5!(7%)! 5!(7%)! 37!(54%)! 4!(6%)! 7! 12!(17%)! 2!(3%)! 4!(6%)!
Nigeria! 1991! Abiose48! 75! 10!(13%)! 3!(4%)! 20!(27%)! 4!(5%)! 25!(33%)! 11!(15%)! 7! 2!(3%)!
Nigeria! 2002! Adewole49! 58! 4!(7%)! 10!(17%)! 11!(19%)! 10!(17%)! 7! 10!(17%)! 7! 13!(22%)!
Nigeria! 2011! Adeyemi50! 181! 9!(5%)! 16!(9%)! 84!(46%)! 8!(4%)! 36!(20%)! 28!(15%)! 7! 7!
Nigeria! 2007! Ajayi51! 112! 2!(2%)! 5!(4%)! 63!(56%)! 8!(7%)! 13!(12%)! 7! 10!(9%)! 11!(10%)!
Nigeria! 2004! Amusa52! 24! 1!(4%)! 7! 10!(42%)! 7! 4!(17%)! 3!(13%)! 6!(25%)! 7!
Nigeria! 1999! Arotiba53! 246! 16!(7%)! 13!(5%)! 82!(33%)! 16!(7%)! 57!(23%)! 48!(20%)! 7! 14!(6%)!
Nigeria! 2006! Arotiba54! 91! 4!(4%)! 10!(11%)! 14!(15%)! 9!(10%)! 23!(25%)! 23!(25%)! 7!(8%)! 1!(1%)!
Nigeria! 2008! Effiom55! 233! 18!(8%)! 31!(13%)! 128!(55%)! 15!(6%)! 7! 41!(18%)! 7! 7!
Nigeria! 2011! Lawal56! 32! 7! 7! 7! 7! 7! 7! 7! 32!(100%)!
Nigeria! 1997! Lawoyin57! 90! 15!(17%)! 6!(7%)! 7!(8%)! 2!(2%)! 36!(40%)! 22!(24%)! 2!(2%)! 7!
Nigeria! 2007! Oji58! 81! 12!(15%)! 7! 7! 17!(21%)! 7! 24!(30%)! 7! 28!(35%)!
Nigeria! 2005! Otoh59! 28! 5!(18%)! 2!(7%)! 3!(11%)! 4!(14%)! 8!(29%)! 3!(11%)! 7! 3!(11%)!
Nigeria! 2000! Rafindadi60! 115! 7! 7! 7! 7! 7! 7! 7! 115!(100%)!
Total!   7750! 290!(4%)! 368!(5%)! 1007 
(13%)!
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Table 2: Included studies of head and neck squamous cell carcinoma of the nasopharynx, nasal cavity, and paranasal sinuses in sub-Saharan 
Africa since 1990
COUNTRY( YEAR! AUTHOR! N! SITES! ! ! !
( ! ! ! Nasal(cavity! Nasopharynx! Maxillary(sinus! Not(specified!
Eastern!        
Kenya! 1998! Oburra61! 34! 1! 2!(6%)! 1! 32!(94%)!
Kenya! 1995! Onyango42! 11! 1! 1! 11!(100%)! 1!
Southern!        
Zimbabwe! 2006! Chidzonga46! 45! 1! 1! 45!(100%)! 1!
Western!        
Nigeria! 2010! Afolabi62! 34! 1! 34!(100%)! 1! 1!
Nigeria! 2004! Amusa52! 9! 1! 8!(89%)! 1!(11%)! 1!
Nigeria! 1998! Arotiba63! 73! 1! 1! 73!(100%)! 1!
Nigeria! 2006! Arotiba54! 70! 1! 1! 70!(100%)! 1!
Nigeria! 2007! Fansula64! 69! 1! 1! 1! 69!(100%)!
Nigeria! 1999! da!Lilly1Tariah65! 43! 1! 43!(100%)! 1! 1!
Nigeria! 2003! da!Lilly1Tariah66! 22! 1! 1! 1! 22!(100%)!
Total!   410!  87!(21%)! 200!(49%)! 123!(30%)!
 
Table 3: Included studies of head and neck squamous cell carcinoma of the larynx in sub-Saharan Africa since 1990
COUNTRY! YEAR! AUTHOR! N! SITES!      
    Supraglottic! Glottic! Subglottic! Transglottic! Not;specified!  
Eastern!          
Kenya! 1998! Oburra
61
! 22! 0! 0! 0! 0! 22!(100%)!  










114! 30!(26%)! 71!(62%)! 2!(2%)! 0! 11!(10%)!  
Western!          
Cameroon! 2006! Oyono
68
! 10! 0! 0! 0! 0! 10!(100%)!  
Nigeria! 2004! Amusa52! 6! 0! 0! 0! 0! 6!(100%)!  
Nigeria! 2009! Amusa
69
! 13! 0! 0! 0! 0! 13!(100%)!  
Nigeria! 2011! Iseh
70
! 20! 0! 0! 0! 20!(100%)! 0!  
Nigeria! 2002! Nwaorgu
71
! 72! 10!(14%)! 40!(56%)! 0! 0! 22!(31%)!  
Nigeria! 2003! Somefun
72
! 36! 3!(8%)! 21!(57%)! 5!(14%)! 8!(22%)! 0!  
Togo! 1999! Kpemissi
73
! 33! 0! 16!(50%)! 0! 14!(44%)! 2!(6%)!  
Total!   385! 43!(11%)! 148!(38%)! 7!(2%)! 42!(11%)! 145!(38%)!  
RSA!=!Republic!of!South!Africa!
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all patients; 30 (37%) were pyriform sinus, 18 (22%) were 
posterior pharyngeal wall, seven (9%) were oesophageal 
introitus, four (5%) were postcricoid, and 22 (27%) were too 
advanced to determine a primary subsite.
Substance use
Only 527 (7%) of  the 7750 OP/OC SCC patients had 
traditional behavioural risk factors reported, with 35% of  
them having used tobacco and 32% having used alcohol 
(Table 4). Data regarding tobacco and alcohol use were 
available for 335 (87%) of  the 385 patients with laryngeal 
SCC and demonstrated that 56% of  patients used tobacco 
and 56% used alcohol (Table 4). Among hypopharyngeal 
SCCs, one study of  15 patients (aged 10 to 18 years) noted 
that no patient used tobacco or alcohol,75 while another 
study noted that 13 (20%) of  66 of  patients used tobacco, 
with alcohol use not reported.74 Duration and amount of  use 
was not consistently reported, and no study specified how 
tobacco or alcohol use was determined. As shown in Table 4, 
the proportion of  patients who reported alcohol and tobacco 
use ranged widely across individual studies. A study in South 
Africa reported 96% and 88% of  men using tobacco and 
alcohol, respectively,45 while a study from Nigeria reported 
only 14% use of  each substance.72 Several studies reporting 
nil alcohol use among HNSCC patients were conducted in 
predominantly Muslim populations and noted that patients 
self-reporting alcohol use would not be socially acceptable. 
Table 4: Tobacco and alcohol use by country and HNSCC site among 
included studies from sub-Saharan Africa since 1990
use by anatomic site were not reported.36 A second Sudanese 
study showed that 67% of  patients with OP/OC SCC used 
toombak.35 Toombak use was most common in SCC of  the 
oral mucosa, of  which 83% of  patients were users. Least 
commonly, only 40% of  tongue SCC patients reported 
toombak use. Oropharynx subsites were not indicated 
separately. Other studies did not report smokeless tobacco 
use separately. Another potentially associated substance is 
kola nut, a stimulant used both socially and ceremonially 
in many forested regions of  sub-Saharan Africa.76 The raw 
product can be chewed or the nut can be processed into a 
beverage. A study from Nigeria observed that four of  five 
patients with OP/OC SCC reported using kola nut.59
HIV and HPV
Two studies prospectively identified HIV-infected patients 
with OC/OP tumours but did not compare this group 
to HIV-uninfected patients.38,39 In the first study, 16 HIV-
infected patients with OC/OP SCC were identified, 
including five with SCC of  the tongue, three of  the floor 
of  the mouth, two of  the gingivae, two with OP SCC, 
two with lip SCC, and two with buccal mucosa SCC. The 
mean or median age was 32 years, and 44% were male. The 
authors also found that 63% of  cancers were high-grade, 
poorly differentiated malignancies, and 44% were stage IV 
at presentation. It was noted that 25% and 31% of  patients 
reported tobacco and alcohol use, respectively.38 The other 
study identified nine HIV-infected patients with HNSCC, 
with a mean age of  36, including two palatal, and seven 
alveolar ridge tumours.39 Treatment and outcomes were not 
described in either study. Other studies anecdotally reported 
that HIV-infected patients had worse outcomes and were 
often not surgical candidates. However, no study described 
patient characteristics or outcomes in HIV-infected and HIV-
uninfected HNSCC populations separately for comparison.
One study tested 155 OP/OC SCC specimens from patients 
in eight countries using PCR for HPV, herpes simplex 
virus (HSV), and Epstein-Barr virus (EBV).36 Tumour 
HPV positivity was highest in Sudan, the only country in 
sub-Saharan Africa included in the study. No mention was 
made of  patient demographics, site, stage, HIV status, or 
behavioural risk factors, in relation to tumour HPV status. 
Additionally, OC and OP tumours were not distinguished 
and analyzed separately. A second study of  217 OP/OC SCC 
specimens in Sudan showed that 25% of  specimens were 
positive for HPV, and that more patients reporting toombak 
use had HPV-positive tumours (27%) than those who did 
not use toombak (21%), although these differences were 
not statistically significant.35 HPV positivity was reported 
by anatomic subsite, however no clear anatomic trends were 
described and oropharynx sites were not designated. One 
study of  15 hypopharyngeal SCCs noted that one patient 
had severe oral and labial papillomatosis, although HPV 
confirmatory testing was not performed.75
Staging, treatment, and outcome
Stage was reported for 543 (6%) of  8611 patients, and late 
presentations were common for all anatomic sites. Overall, 
3% of  HNSCCs were stage I, 6% were stage II, 52% were 
stage III, and 39% were stage IV. No study described 
using nasopharyngoscopy, computed tomography (CT), or 
magnetic resonance imaging (MRI) for staging, and most 
papers reported that these were not available.
Only one of  28 studies describing OP/OC SCC reported 
COUNTRY( AUTHOR! SITE( n*! TOBACCO(USE(n((%)! ALCOHOL(USE(n((%)!
Central!      
Sudan! Ibrahim
33
! OP/OC! 192! 26!(14%)! 24!(13%)!
Sudan! Jalouli
36
! OP/OC! 20! 15!(75%)! 0!(0%)!
Eastern!      
Kenya! Butt
39
! OP/OC! 16! 4!(25%)! 5!(31%)!
Southern!      
RSA! PacellaHNorman
45
! OP/OC! 124! 97!(78%)! 94!(76%)!
RSA! PacellaHNorman
45!





Larynx! 114! 57!(50%)! 57!(50%)!
Western!      
Nigeria! Adewole
49
! OP/OC! 50! 30!(60%)! 36!(72%)!
Nigeria! Lawal
56
! OP/OC! 32! 8!(25%)! 8!(25%)!
Nigeria! Oji
58
! OP/OC! 81! 0!(0%)! 0!(0%)!
Nigeria! Otoh
59
! OP/OC! 12! 2!(17%)! 1!(8%)!
Nigeria! Amusa
69
! Larynx! 13! 5!(38%)! 11!(85%)!
Nigeria! Iseh
70
! Larynx! 20! 20!(100%)! 0!(0%)!
Nigeria! Nwaorgu
71
! Larynx! 68! 30!(44%)! 47!(69%)!
Nigeria! Somefun
72
! Larynx! 36! 5!(14%)! 5!(14%)!
Togo! Kpemissi
73
! Larynx! 33! 26!(79%)! 27!(82%)!






Another substance reported to be associated with HNSCC 
is toombak, a fermented and cured tobacco product, 
commonly used—by placing a portion in the buccal 
sulcus—in the northernmost regions of  sub-Saharan Africa. 
One Sudanese study reported that 58% of  patients with lip, 
buccal mucosa, and floor of  mouth cancer used toombak, 
while only 19% of  patients with tongue, palate, and maxillary 
sinus cancer reported the same, though rates of  toombak 
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treatment for 146 patients in Nigeria.53 Twenty-one patients 
(14%) declined treatment, 22 (15%) underwent palliative 
chemotherapy or radiation, and the remainder underwent 
surgery, chemotherapy, radiation, or a combination with 
curative intent. Limited outcomes were reported as 113 
patients (77%) were lost to follow-up within two weeks of  
enrolment. 
Seven of  11 laryngeal SCC studies discuss treatment, and 
all reported patients frequently presenting with airway 
emergencies requiring emergent tracheostomy before 
definitive treatment. Radiotherapy was used alone or with 
other treatment modalities in 70% of  patients, and outcome 
data were limited. Patients from studies in Zimbabwe,67 
Togo,73 Nigeria,69,70 and Cameroon68 received radiation 
therapy. Several studies noted patients who refused treatment, 
though reasons were not given. With respect to treatment 
complications, one series reported five of  33 patients 
developing pharyngocutanenous fistulae.67 In another series 
of  nine patients, two developed pharyngocutaneous fistulae, 
while pharyngeal stenosis, stomal stenosis, hypothyroidism, 
and hypocalcaemia were reported in individual cases.69 
Another series reported pharyngocutaneous fistula in one of  
three patients who underwent surgery and radiation.68 One 
series of  five patients who underwent postoperative radiation 
noted that two died from carotid artery rupture.70 Rates 
of  mucositis, malnutrition, and infectious complications, 
common causes of  treatment-related morbidity in resource-
rich settings, were not reported in any study.
Among HP SCCs,74,75 two patients (3%) underwent surgery 
followed by radiation, three patients (4%) underwent surgery 
alone and 28 patients (35%) underwent radiation alone, 
while 48 (59%) underwent only palliative tracheostomy or 
gastrostomy. Within three years of  follow-up, 77 patients 
(95%) had died and the remaining four (5%) were lost to 
follow-up.
Discussion
To our knowledge, this is the first systematic review of  the 
existing literature of  HNSCC in sub-Saharan Africa.
Obstacles to collecting accurate data with respect to age 
in sub-Saharan Africa are well described.77 In the studies 
reviewed, however, age at presentation was approximately 
20 years younger for HNSCC patients than in the US.78,79 
Younger age at diagnosis compared with high-income 
countries has been consistently noted for many cancers in 
sub-Saharan Africa, and this may reflect biologic differences 
with respect to cancer pathogenesis and susceptibility, or 
differences in population age structure, or a combination of  
both factors.8
Established risk factors for HNSCC in high-income countries 
include smoking, alcohol use, and older age. Overall, of  the 
sub-Saharan HNSCC patients for whom environmental 
exposures were reported, more than half  were non-smokers 
and denied alcohol use, implying a different set of  risk 
factors compared to high-income countries. However, the 
data are difficult to analyze. Several studies noted the overall 
prevalence of  tobacco and alcohol use among HNSCC cases, 
but very few reported the actual number of  patients using 
these substances or the prevalence of  tobacco and alcohol 
use in the general population. Some studies noted that 
social norms might prevent patients from openly reporting 
substance use, an inherent limitation of  self-reported data.80
Clearer descriptions of  anatomy and stage would lead to a 
better understanding of  HNSCC in sub-Saharan Africa. In 
high-income countries, the incidence of  HNSCC attributable 
to tobacco and alcohol is decreasing,81 while incidence of  
HPV-associated oropharyngeal SCC is increasing.82 In 
the reviewed studies, only 2% of  OC/OP cases specified 
OP as the site, although many papers described tongue or 
palate tumours that spanned both OC and OP.  The lack of  
advanced imaging and nasopharyngoscopy severely limits the 
ability of  providers to make distinctions regarding anatomic 
sites and disease stage. The scarcity of  staging information 
may also be due to a lack of  familiarity among providers 
with the complex anatomy and staging of  HNSCC. These 
distinctions have implications in prognosis and treatment. In 
high-income countries, HPV-positive OP SCC patients have 
better outcomes than HPV-negative OP patients (and those 
with HNSCC in other sites)83,84 and are increasingly treated 
with deintensification strategies, which include surgery as a 
single modality.85 Surgery is available in many sub-Saharan 
African countries where radiotherapy is not and, therefore, 
distinguishing OP from OC SCC might influence treatment 
recommendations. 
One study from Sudan reported that two-thirds of  OP/
OC SCCs were positive for HPV,36 while a second study 
from Sudan reported one-quarter of  OP/OC SCC to be 
positive.35 Another study, which did not meet criteria for 
inclusion because of  missing clinical data, found only two of  
146 OP/OC SCCs from black South Africans to be positive 
for HPV (subtypes 6, 11, 16, 18).23 Another study of  three 
female patients with laryngeal cancer in Congo noted one 
tumour to be histologically consistent with HPV, although no 
confirmatory testing was done.86,87 These conflicting results 
underscore the need for further research into the role of  
HPV in HNSCC in sub-Saharan Africa. HPV vaccination is 
a high priority for many ministries of  health throughout the 
region, to reduce the immense burden of  cervical cancer.88,89 
If  HPV is a significant contributor to HNSCC, introducing 
HPV vaccination may reduce HNSCC burden, in addition to 
reducing cervical and anal cancer. Long-term monitoring of  
HNSCC incidence in countries where HPV vaccination has 
been introduced will be highly informative.
In the US, HIV infection is associated with a two- to three-
fold increased risk of  HNSCC,90 although whether this 
results from increasing mucosal HPV rates and greater 
susceptibility to HPV oncogenesis, increased tobacco and 
alcohol use, or both, is uncertain.91 Limited data suggest that 
HIV-infected HNSCC patients in sub-Saharan Africa may 
be younger, with infrequent tobacco and alcohol use, more 
aggressive cancers, and worse clinical outcomes.38,39 The 
effect of  antiretroviral therapy (ART) scale-up on cancer 
incidence overall, and HNSCC incidence specifically, remains 
uncertain. Further cancer research in settings with high HIV 
prevalence can clarify these relationships and inform both 
ART and cancer treatment programmes.
HNSCC is frequently treated with surgery. General surgeons 
can perform diagnostic biopsies and tracheostomies when 
indicated, but there is an extreme scarcity of  head and 
neck surgeons to perform curative surgeries for HNSCC 
in sub-Saharan Africa. A survey of  18 sub-Saharan African 
countries in 2008 identified one ENT surgeon per million 
population. If  South Africa is excluded, there were 0.6 ENT 
surgeons per million population,92 compared with 28 per 
million population in the US.93,94 Pathology services are also 
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lacking, with less than one pathologist per million population 
in Nigeria,95 Tanzania,96 and Uganda,97 versus 51 per million 
population in the US.94,98 Similarly, there are fewer than one 
medical oncologist per million population in Ethiopia99,100 
and Malawi compared with 43 per million population in the 
US.94,101
Radiation is also a mainstay of  HNSCC treatment and can be 
used alone, in combination with chemotherapy, or following 
surgery. However, radiotherapy can lead to complications, 
particularly in settings where treatment may be administered 
using older units, without modern techniques to minimize 
toxicity.102 No studies reported rates of  mucositis, infection, 
or malnutrition in patients receiving radiotherapy, although 
these are frequently observed complications in resource-rich 
settings. Even when safely administered, radiotherapy units 
are severely limited throughout sub-Saharan Africa, which 
has only 88 radiotherapy facilities overall, of  which 53 are 
in South Africa or Nigeria. Twenty-seven countries within 
the region have no radiotherapy at all, and of  the countries 
that do administer radiotherapy, most have only a single 
operational unit.103 
HNSCC is a complex disease that is incompletely described 
in sub-Saharan Africa. As with many other disease entities, 
improvement in medical infrastructure will improve 
diagnosis, treatment, and outcomes.
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